Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 164.9%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 105,183 shares, an increase of 164.9% from the January 29th total of 39,712 shares. Approximately 2.4% of the company’s shares are short sold. Based on an average daily volume of 241,624 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 241,624 shares, the short-interest ratio is currently 0.4 days. Approximately 2.4% of the company’s shares are short sold.

Institutional Trading of bioAffinity Technologies

Institutional investors have recently made changes to their positions in the stock. Sabby Management LLC acquired a new stake in shares of bioAffinity Technologies during the 3rd quarter worth $719,000. Geode Capital Management LLC purchased a new stake in bioAffinity Technologies during the fourth quarter valued at about $36,000. Finally, Scientech Research LLC purchased a new stake in bioAffinity Technologies during the third quarter valued at about $49,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

bioAffinity Technologies Price Performance

BIAF opened at $1.04 on Friday. bioAffinity Technologies has a 1 year low of $0.69 and a 1 year high of $46.53. The company’s 50 day simple moving average is $1.18 and its 200 day simple moving average is $2.99. The stock has a market capitalization of $4.68 million, a PE ratio of -0.05 and a beta of 2.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.65.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.